BR112021008870A2 - Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. - Google Patents

Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.

Info

Publication number
BR112021008870A2
BR112021008870A2 BR112021008870A BR112021008870A BR112021008870A2 BR 112021008870 A2 BR112021008870 A2 BR 112021008870A2 BR 112021008870 A BR112021008870 A BR 112021008870A BR 112021008870 A BR112021008870 A BR 112021008870A BR 112021008870 A2 BR112021008870 A2 BR 112021008870A2
Authority
BR
Brazil
Prior art keywords
antibody
polynucleotides
composition
treating cancer
antibodies
Prior art date
Application number
BR112021008870A
Other languages
English (en)
Inventor
Bingshi Guo
Byungje Sung
Eunsil Sung
Eunyoung Park
Lei Fang
Wenqing Jiang
Zhengyi Wang
Original Assignee
Abl Bio Inc
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc, I Mab Biopharma Us Ltd filed Critical Abl Bio Inc
Publication of BR112021008870A2 publication Critical patent/BR112021008870A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. são providos anticorpos biespecíficos e multiespecíficos que têm como alvo a claudina 18.2 (cldn18.2) e 4-1bb. esses anticorpos, na ausência de células que expressam cldn18.2, podem se ligar a 4-1bb, mas são incapazes de ativar a sinalização de 4-1bb. na presença de células que expressam cldn18.2, no entanto, esses anticorpos podem desencadear a sinalização 4-1bb dependente de cldn18.2, levando a uma potente resposta imune às células tumorais que expressam cldn18.2.
BR112021008870A 2019-08-12 2020-08-12 Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. BR112021008870A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019100162 2019-08-12
CN2019104508 2019-09-05
CN2020071954 2020-01-14
CN2020087968 2020-04-30
PCT/CN2020/108707 WO2021027850A1 (en) 2019-08-12 2020-08-12 Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112021008870A2 true BR112021008870A2 (pt) 2021-11-30

Family

ID=74570528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021008870A BR112021008870A2 (pt) 2019-08-12 2020-08-12 Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.

Country Status (16)

Country Link
US (2) US11261259B2 (pt)
EP (1) EP3853257A4 (pt)
JP (2) JP7410141B2 (pt)
KR (1) KR20210082482A (pt)
CN (1) CN113166265B (pt)
AU (1) AU2020329466A1 (pt)
BR (1) BR112021008870A2 (pt)
CA (1) CA3117740A1 (pt)
CL (1) CL2021001375A1 (pt)
CO (1) CO2021006953A2 (pt)
IL (1) IL283379A (pt)
MX (1) MX2021006428A (pt)
PE (1) PE20211147A1 (pt)
PH (1) PH12021551269A1 (pt)
SG (1) SG11202104131VA (pt)
WO (1) WO2021027850A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4004053A4 (en) * 2019-07-26 2023-10-18 ABL Bio, Inc. BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODIES AND USE THEREOF
AU2022330225A1 (en) * 2021-08-18 2024-02-29 Biotheus Inc. Bispecific antibody and use thereof
CN116410326A (zh) * 2021-12-30 2023-07-11 三优生物医药(上海)有限公司 抗cd40×cldn18.2双特异性抗体及其用途
WO2023134657A1 (zh) * 2022-01-11 2023-07-20 原启生物科技(上海)有限责任公司 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
WO2023222135A1 (en) * 2022-05-20 2023-11-23 I-Mab Biopharma Co., Ltd. A method of treating solid tumor
WO2023232140A1 (en) * 2022-06-03 2023-12-07 Lanova Medicines Development Co., Ltd. Cancer treatment with a pd-1 or pd-l1 inhibitor and an antibody-drug conjugates targeting claudin 18.2
WO2024114676A1 (zh) * 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
RU2678127C2 (ru) 2012-11-13 2019-01-23 Бионтех Аг Агенты для лечения экспрессирующих клаудин раковых заболеваний
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
US10858415B2 (en) * 2014-01-29 2020-12-08 Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh Peptide mimotopes of claudin 18.2 and uses thereof
JP7366541B2 (ja) * 2016-02-19 2023-10-23 コード バイオセラピューティクス インコーポレイテッド 核酸キャリア及び治療上の使用方法
CN117752798A (zh) * 2016-12-19 2024-03-26 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
US20200188528A1 (en) * 2016-12-19 2020-06-18 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
AU2017384126A1 (en) * 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
AU2018206138A1 (en) * 2017-01-03 2019-07-11 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9
EP3574018A4 (en) 2017-01-27 2020-10-07 Silverback Therapeutics, Inc. CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
KR20200080304A (ko) * 2017-11-13 2020-07-06 크레센도 바이오로직스 리미티드 Cd137에 결합하는 단일 도메인 항체
BR112021010402A2 (pt) * 2018-11-30 2021-08-24 Abl Bio Inc. Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof

Also Published As

Publication number Publication date
JP2023182853A (ja) 2023-12-26
EP3853257A4 (en) 2022-06-29
WO2021027850A1 (en) 2021-02-18
KR20210082482A (ko) 2021-07-05
AU2020329466A1 (en) 2021-05-27
MX2021006428A (es) 2021-11-17
JP2022543508A (ja) 2022-10-13
CN113166265A (zh) 2021-07-23
US11261259B2 (en) 2022-03-01
CN113166265B (zh) 2024-06-04
CO2021006953A2 (es) 2021-08-19
US20210317224A1 (en) 2021-10-14
JP7410141B2 (ja) 2024-01-09
SG11202104131VA (en) 2021-05-28
PH12021551269A1 (en) 2021-11-03
CL2021001375A1 (es) 2022-01-07
PE20211147A1 (es) 2021-06-28
EP3853257A1 (en) 2021-07-28
IL283379A (en) 2021-07-29
US20220348675A1 (en) 2022-11-03
CA3117740A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
BR112021008870A2 (pt) Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
BR112018010085A2 (pt) ligantes de pd1/ctla4
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
WO2019126514A3 (en) Antibodies to lilrb2
NZ767596A (en) Antibodies that bind cd39 and uses thereof
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
CL2018001326A1 (es) Proteínas de unión a ctla4.
MX2018006072A (es) Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
BR112018002824A2 (pt) anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
BR112017020054A2 (pt) anticorpos para icos
PE20210110A1 (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BR112018009645A2 (pt) composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2020004561A (es) Anticuerpos biespecificos que se unen a alk-1 y bmpr-2.
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
EP4268848A3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
BR112018000584A2 (pt) proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas
CY1125041T1 (el) Αντισωματα anti-il-22r
PE20200010A1 (es) Anticuerpos que se unen a steap-1
BR112017027252A2 (pt) imunoglobulinas conjugadas a cys80